Overview

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer

Status:
RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).

Phase:

PHASE2

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Aromatase Inhibitors
Tamoxifen